Remove Antibody Remove Compound Screening Remove FDA Approval Remove Licensing
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . But according to Erhardt, most are counting on antibody programs targeting beta amyloid or tau.